bioRxivMicrobiologyPreprint
Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
C. Wang, S. Wang, D. Li, X. Zhao, S. Han, T. Wang, G. Zhao, Y. Chen, F. Chen, J. Zhao, L. Wang, W. Sun, Y. Huang, Y. Su, D. Wei, J. Zhao, J. Wang
Abstract
The burgeoning epidemic caused by novel coronavirus 2019 (2019-nCoV) is currently a global concern. Angiotensin-converting enzyme-2 (ACE2) is a receptor of 2019-nCoV spike 1 protein (S1) and mediates viral entry into host cells. Despite the abundance of ACE2 in small intestine, few digestive symptoms are observed in patients infected by 2019-nCoV. Herein, we investigated the interactions between ACE2 and human defensins (HDs) specifically secreted by intestinal Paneth cells. The lectin-like HD5, rather than HD6, bound ACE2 with a high affinity of 39.3 nM and weakened the subsequent recruitment of 2019-nCoV S1. The cloak of HD5 on the ligand-binding domain of ACE2 was confirmed by molecular dynamic simulation. A remarkable dose-dependent preventive effect of HD5 on 2019-nCoV S1 binding to intestinal epithelial cells was further evidenced by in vitro experiments. Our findings unmasked the innate defense function of lectin-like intestinal defensin against 2019-nCoV, which may provide new insights into the prevention and treatment of 2019-nCoV infection.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- hACE2 peptide mimics block SARS-CoV-2 Pulmonary Cells Infection
P. Karoyan, V. Vieillard, … O. Lequin·bioRxiv·Aug 24, 2020
- Increasing Host Cellular Receptor--Angiotensin-Converting Enzyme 2 (ACE2) Expression by Coronavirus may Facilitate 2019-nCoV Infection
P.-H. Wang·bioRxiv·Feb 24, 2020
- The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Markus Hoffmann, Hannah Kleine‐Weber, … Stefan Pöhlmann·CellPeer-reviewed·Mar 8, 2020
- Molecular dynamics simulations and functional studies reveal that hBD-2 binds SARS-CoV-2 spike RBD and blocks viral entry into ACE2 expressing cells
L. Zhang, S. K. Ghosh, … A. Weinberg·bioRxiv·Jan 7, 2021
- Intranasal Administration of ACIS KEPTIDE™ Prevents SARS-CoV2-Induced Acute Toxicity in K18-hACE2 Humanized Mouse Model of COVID-19: A Mechanistic Insight for the Prophylactic Role of KEPTIDE™ in COVID-19
G. Gottschalk, J. F. Keating, … A. Roy·bioRxiv·Nov 13, 2020
- Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection